SIETES :: 92824 citas

Resultados de la búsqueda por SULFASALACINA REFINAR BÚSQUEDA

1.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

2.

Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case–control study. Drug Saf 2019;42:enero. [Ref.ID 103028]

3.

Anónimo. Baricitinib et polyarthrite rhumatoïde. Prescrire 2018;38:171-2. [Ref.ID 102586]

4.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

5.

Wadström H, Frisell T, Askling J, for the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. A nationwide cohort study from Sweden. JAMA Intern Med 2017;177:1605-12. [Ref.ID 102143]

6.

Anónimo. Maladies auto-immunes d'origine médicamenteuse. Prescrire 2017;37:346-53. [Ref.ID 101654]

7.

Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Med Clin (Barc) 2016;147:352-60. [Ref.ID 100793]

8.

Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]

9.

Anónimo. Drugs for rheumatoid arthritis. Med Lett Drugs Ther 2014;56:127-32. [Ref.ID 98445]

10.

Anónimo. Vertiges vrais et troubles de l'équilibre d'origine médicamenteuse, en bref. Prescrire 2014;34:431. [Ref.ID 97949]

11.

Anónimo. Pertes d'auditions d'origine médicamenteuse. Prescrire 2014;34:428-35. [Ref.ID 97948]

12.

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis & Rheumatology 2014;66:803-12. [Ref.ID 97506]

13.

Anónimo. Écraser un comprimé ou ouvrir une gélule: beaucoup d'incertitudes, quelques dangers avérés. Prescrire 2014;34:267-73. [Ref.ID 97441]

14.

Huber M, Andersohn F, Bronder E, Klimpel A, Thomae M, Konzen Ch, Meyer O, Salama A, Schrezenmeier H, Hildebrandt M, Späth-Schawalbe E, Grüneisen A, Kreutz R, Garbe E. Drug-induced agranulocytosis in the Berlin case–control surveillance study. Eur J Clin Pharmacol 2014;70:339-45. [Ref.ID 97278]

15.

Yelin E. Not better but quite good: effects on work loss of combination treatment for rheumatoid arthritis with and without biological agents. JAMA Intern Med 2013;173:1414-5. [Ref.ID 95977]

16.

Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, Emestam S. Biological vs conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. JAMA Intern Med 2013;173:1407-14. [Ref.ID 95974]

17.

O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone EC, for the CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18. [Ref.ID 95876]

18.

Bathon JM, McMahon DJ. Making rational treatment decisions in rheumatoid arthritis when methotrexate fails. N Engl J Med 2013;369:384-5. [Ref.ID 95655]

19.

Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [Ref.ID 95460]

20.

Anónimo. Syndrome d'hypersensibilité multiorganique d'origine médicamenteuse. Prescrire 2012;32:832. [Ref.ID 93980]